Table 2

Changes in plasma angiotensin II, aldosterone, and urinary sodium concentration with and without ACE inhibition

Placebo ACE inhibitor Changes
Angiotensin II (pmol/l)
Low PRA7.5 (4.8)4.3 (3.2)3.2 (3.7) (95% CI 0.8 to 5.7); p = 0.015
Normal PRA11.4 (7.7)2.74 (2.3)8.7 (7.0) (95% CI 4.5 to 12.9); p = 0.001
High PRA49.0 (46.4)3.8 (3.3)45.2 (45.8) (95% CI 17.5 to 72.8); p = 0.004
2-150p < 0.001p = 0.419
Aldosterone (pmol/l)
Low PRA262 (146)219 (158)42 (88) (95% CI −16 to 102); p = 0.138
Normal PRA336 (172)234 (235)102 (167) (95% CI 2 to 203); p = 0.047
High PRA599 (312)260 (118)338 (281) (95% CI 149 to 527); p = 0.003
2-150p < 0.001p = 0.948
Urine sodium (mmol/l)
Low PRA96.7 (39.5)101.8 (33.6)−5.1 (23.6) (95% CI −21.0 to 10.8); p = 0.491
Normal PRA90.4 (26.7)94.5 (33.1)−4.1 (24.0) (95% CI −18.6 to 10.4); p = 0.551
High PRA66.3 (18.9)80.8 (22.5)−14.6 (21.3) (95% CI −27.4 to −1.73); p = 0.02
2-150p = 0.033p = 0.231
  • 2-150 Post hoc pairwise comparisons suggested that the plasma angiotensin II and aldosterone levels were not different between the low and normal PRA groups, but the levels of these hormones were significantly higher in the high PRA groups than in either low or normal PRA groups.

  • ACE, angiotensin converting enzyme; PRA, plasma renin activity.